Spyre Therapeutics, Inc. Research And Development Expense

Quick Answer

Spyre Therapeutics, Inc. reported Research And Development Expense of $58.58 million for the year ending 2022.

  • Spyre Therapeutics, Inc. showed an increase of +2.6% in Research And Development Expense from 2021 to 2022.
  • This data is from Spyre Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2023.
  • XBRL data for this metric is available from 2014 to 2022 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 9 years of available data (2014 to 2022), Spyre Therapeutics, Inc.'s Research And Development Expense has grown by 757.7%.
  • Historical annual values: Fiscal year 2022: $58.58 million | Fiscal year 2021: $57.07 million | Fiscal year 2020: $59.64 million | Fiscal year 2019: $64.60 million | Fiscal year 2018: $36.72 million | Fiscal year 2017: $22.82 million | Fiscal year 2016: $18.14 million | Fiscal year 2015: $11.45 million | Fiscal year 2014: $6.83 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: